Logo image of NEOG

NEOGEN CORP (NEOG) Stock Fundamental Analysis

NASDAQ:NEOG - Nasdaq - US6404911066 - Common Stock - Currency: USD

5.2  +0.28 (+5.69%)

After market: 5.2 0 (0%)

Fundamental Rating

4

Overall NEOG gets a fundamental rating of 4 out of 10. We evaluated NEOG against 191 industry peers in the Health Care Equipment & Supplies industry. NEOG has an average financial health and profitability rating. NEOG has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year NEOG was profitable.
In the past year NEOG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
In the past 5 years NEOG always reported a positive cash flow from operatings.
NEOG Yearly Net Income VS EBIT VS OCF VS FCFNEOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

With a Return On Assets value of -12.02%, NEOG perfoms like the industry average, outperforming 59.16% of the companies in the same industry.
Looking at the Return On Equity, with a value of -18.24%, NEOG is in the better half of the industry, outperforming 63.35% of the companies in the same industry.
The Return On Invested Capital of NEOG (0.50%) is better than 67.02% of its industry peers.
NEOG had an Average Return On Invested Capital over the past 3 years of 2.71%. This is below the industry average of 7.68%.
Industry RankSector Rank
ROA -12.02%
ROE -18.24%
ROIC 0.5%
ROA(3y)1.38%
ROA(5y)3.65%
ROE(3y)1.47%
ROE(5y)3.97%
ROIC(3y)2.71%
ROIC(5y)4.4%
NEOG Yearly ROA, ROE, ROICNEOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8 10

1.3 Margins

NEOG has a Operating Margin of 2.72%. This is in the better half of the industry: NEOG outperforms 68.59% of its industry peers.
In the last couple of years the Operating Margin of NEOG has declined.
With a Gross Margin value of 48.79%, NEOG perfoms like the industry average, outperforming 41.36% of the companies in the same industry.
In the last couple of years the Gross Margin of NEOG has grown nicely.
Industry RankSector Rank
OM 2.72%
PM (TTM) N/A
GM 48.79%
OM growth 3Y-20.27%
OM growth 5Y-13.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.02%
GM growth 5Y1.61%
NEOG Yearly Profit, Operating, Gross MarginsNEOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NEOG is destroying value.
NEOG has about the same amout of shares outstanding than it did 1 year ago.
NEOG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NEOG is higher compared to a year ago.
NEOG Yearly Shares OutstandingNEOG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
NEOG Yearly Total Debt VS Total AssetsNEOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

NEOG has an Altman-Z score of 0.89. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.89, NEOG is in line with its industry, outperforming 52.36% of the companies in the same industry.
A Debt/Equity ratio of 0.33 indicates that NEOG is not too dependend on debt financing.
The Debt to Equity ratio of NEOG (0.33) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z 0.89
ROIC/WACC0.05
WACC9.65%
NEOG Yearly LT Debt VS Equity VS FCFNEOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

NEOG has a Current Ratio of 3.91. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.91, NEOG is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
NEOG has a Quick Ratio of 2.45. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.45, NEOG is in line with its industry, outperforming 59.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 2.45
NEOG Yearly Current Assets VS Current LiabilitesNEOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

3

3. Growth

3.1 Past

The earnings per share for NEOG have decreased strongly by -20.83% in the last year.
Measured over the past years, NEOG shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.21% on average per year.
The Revenue has decreased by -2.50% in the past year.
The Revenue has been growing by 17.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-20.83%
EPS 3Y-8.53%
EPS 5Y-5.21%
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y25.42%
Revenue growth 5Y17.41%
Sales Q2Q%-3.42%

3.2 Future

The Earnings Per Share is expected to grow by 6.10% on average over the next years.
Based on estimates for the next years, NEOG will show a small growth in Revenue. The Revenue will grow by 1.81% on average per year.
EPS Next Y-14.23%
EPS Next 2Y-1.33%
EPS Next 3Y3.62%
EPS Next 5Y6.1%
Revenue Next Year-1.36%
Revenue Next 2Y0.98%
Revenue Next 3Y1.9%
Revenue Next 5Y1.81%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NEOG Yearly Revenue VS EstimatesNEOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NEOG Yearly EPS VS EstimatesNEOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.68, NEOG is valued correctly.
NEOG's Price/Earnings ratio is rather cheap when compared to the industry. NEOG is cheaper than 90.05% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.92. NEOG is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 12.14 indicates a correct valuation of NEOG.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NEOG indicates a rather cheap valuation: NEOG is cheaper than 91.10% of the companies listed in the same industry.
NEOG's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.65.
Industry RankSector Rank
PE 13.68
Fwd PE 12.14
NEOG Price Earnings VS Forward Price EarningsNEOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

83.25% of the companies in the same industry are more expensive than NEOG, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.27
NEOG Per share dataNEOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.33%
EPS Next 3Y3.62%

0

5. Dividend

5.1 Amount

No dividends for NEOG!.
Industry RankSector Rank
Dividend Yield N/A

NEOGEN CORP

NASDAQ:NEOG (4/24/2025, 8:00:02 PM)

After market: 5.2 0 (0%)

5.2

+0.28 (+5.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-09 2025-04-09/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners121.73%
Inst Owner Change0.16%
Ins Owners0.23%
Ins Owner Change18.27%
Market Cap1.13B
Analysts82
Price Target14.96 (187.69%)
Short Float %10.65%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.34%
Min EPS beat(2)-10.87%
Max EPS beat(2)11.56%
EPS beat(4)1
Avg EPS beat(4)-8.33%
Min EPS beat(4)-19.26%
Max EPS beat(4)11.56%
EPS beat(8)2
Avg EPS beat(8)50.77%
EPS beat(12)4
Avg EPS beat(12)43.66%
EPS beat(16)4
Avg EPS beat(16)25.09%
Revenue beat(2)0
Avg Revenue beat(2)-1.93%
Min Revenue beat(2)-3.66%
Max Revenue beat(2)-0.19%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)2.8%
Revenue beat(8)2
Avg Revenue beat(8)-0.83%
Revenue beat(12)2
Avg Revenue beat(12)-1.27%
Revenue beat(16)4
Avg Revenue beat(16)-0.85%
PT rev (1m)0%
PT rev (3m)-9.28%
EPS NQ rev (1m)-30.77%
EPS NQ rev (3m)-45.45%
EPS NY rev (1m)-11.9%
EPS NY rev (3m)-19.57%
Revenue NQ rev (1m)-6.38%
Revenue NQ rev (3m)-13.01%
Revenue NY rev (1m)-1.03%
Revenue NY rev (3m)-3.67%
Valuation
Industry RankSector Rank
PE 13.68
Fwd PE 12.14
P/S 1.25
P/FCF N/A
P/OCF 16.49
P/B 0.42
P/tB N/A
EV/EBITDA 13.27
EPS(TTM)0.38
EY7.31%
EPS(NY)0.43
Fwd EY8.24%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)0.32
OCFY6.06%
SpS4.17
BVpS12.26
TBVpS-2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.02%
ROE -18.24%
ROCE 0.63%
ROIC 0.5%
ROICexc 0.52%
ROICexgc 2.96%
OM 2.72%
PM (TTM) N/A
GM 48.79%
FCFM N/A
ROA(3y)1.38%
ROA(5y)3.65%
ROE(3y)1.47%
ROE(5y)3.97%
ROIC(3y)2.71%
ROIC(5y)4.4%
ROICexc(3y)3.97%
ROICexc(5y)7.43%
ROICexgc(3y)14.92%
ROICexgc(5y)18.11%
ROCE(3y)3.43%
ROCE(5y)5.58%
ROICexcg growth 3Y-23.14%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-51.38%
ROICexc growth 5Y-36.83%
OM growth 3Y-20.27%
OM growth 5Y-13.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.02%
GM growth 5Y1.61%
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA 6.24
Cap/Depr 95.45%
Cap/Sales 12.44%
Interest Coverage 250
Cash Conversion 47.97%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 2.45
Altman-Z 0.89
F-Score4
WACC9.65%
ROIC/WACC0.05
Cap/Depr(3y)91%
Cap/Depr(5y)106.13%
Cap/Sales(3y)8.23%
Cap/Sales(5y)7.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.83%
EPS 3Y-8.53%
EPS 5Y-5.21%
EPS Q2Q%-16.67%
EPS Next Y-14.23%
EPS Next 2Y-1.33%
EPS Next 3Y3.62%
EPS Next 5Y6.1%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y25.42%
Revenue growth 5Y17.41%
Sales Q2Q%-3.42%
Revenue Next Year-1.36%
Revenue Next 2Y0.98%
Revenue Next 3Y1.9%
Revenue Next 5Y1.81%
EBIT growth 1Y-66.32%
EBIT growth 3Y-0.01%
EBIT growth 5Y1.73%
EBIT Next Year62.88%
EBIT Next 3Y24.17%
EBIT Next 5Y15.27%
FCF growth 1Y46.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y331.64%
OCF growth 3Y-24.24%
OCF growth 5Y-11.19%